Trials / Completed
CompletedNCT03015207
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 22 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0194-0499 | |
| DRUG | Placebo |
Timeline
- Start date
- 2017-01-06
- Primary completion
- 2017-10-26
- Completion
- 2017-10-26
- First posted
- 2017-01-09
- Last updated
- 2018-09-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03015207. Inclusion in this directory is not an endorsement.